TITLE

LUNG ALERT: Thrombolysis for submassive pulmonary embolism

AUTHOR(S)
Seemungal, T. A. R.
PUB. DATE
January 2003
SOURCE
Thorax;Jan2003, Vol. 58 Issue 1, p72
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Investigates the use of thrombolysis for submassive pulmonary embolism. Criteria for the selection of patients eligible for the study; Comparison between randomized placebo controlled trial of alteplase with heparin versus placebo with heparin; Safety and efficacy of alteplase.
ACCESSION #
16589533

 

Related Articles

  • Management of right heart thrombi associated with acute pulmonary embolism: is there no room for surgical embolectomy? Fukuda, Ikuo; Taniguchi, Satoshi; Fukuda, Wakako // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Sep2013, Vol. 13 Issue 6, p534 

    The authors discuss the approach to treat pulmonary embolism associated with right heart thrombus by referring to an article published in the Anatolian Journal of Cardiology by Akilli and colleagues. They mention that thrombolytic therapy may cause occlusion of patent pulmonary artery and...

  • Successful treatment of massive pulmonary embolism with prolonged catheter-directed thrombolysis. Kelly, Peter; Carroll, Niamh; Grant, Cliona; Barrett, Conor; Kocka, Victor // Heart & Vessels;Mar2006, Vol. 21 Issue 2, p124 

    This is a case report of a young woman who presented with an extensive pulmonary embolism and echocardiographic evidence of right ventricular dysfunction. Although hemodynamically stable, the patient's clinical condition failed to improve with standard heparin anticoagulation. Successful local...

  • Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin. Elliott, Greg; Stevens, Scott // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p41 

    The article presents a research study which reveals that thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin. The researchers concluded that unselected patients with acute pulmonary embolism thrombolysis does not reduce the risk of...

  • LMW heparin effective for pulmonary embolus.  // BMJ: British Medical Journal (International Edition);5/8/2004, Vol. 328 Issue 7448, p1084 

    Presents a medical study to evaluate whether low molecular weight heparin is as effective as adjusted dose heparin in treating pulmonary embolism. Synopsis of the study; Conclusion that low molecular weight heparin is as effective as adjusted dose, unfractionated heparin in treating symptomatic...

  • Michigan State University: Vena cava filters do not lower mortality rate in most embolism cases; Study of 2 mln patients outlines embolism treatments.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article focuses on a research according to which vena cava filters, used to block clots from passing from the veins in the legs to the arteries of the lung, do not improve mortality rates for patients with pulmonary embolism. The study analyzed more than two million patients suffering from...

  • Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. Risch, Lorenz; Fischer, Joachim E.; Herklotz, Roberto; Huber, Andreas R. // Intensive Care Medicine;Aug2004, Vol. 30 Issue 8, p1615 

    Objective: Reports on heparin-induced thrombocytopenia (HIT) in paediatrics are confined to isolated case reports. The objective was to systematically combine the published data.Design and Setting: Cases were identified by MEDLINE search and review of...

  • In-Vitro Evaluation of a New Inferior Vena Cava Filter. de Godoy, José Maria Pereira; Braile, Domingo Marcolino // Vascular & Endovascular Surgery;May/Jun2004, Vol. 38 Issue 3, p225 

    Inferior vena cava filters are indicated for the prevention of pulmonary embolism when anticoagulation using heparin has failed or is contraindicated. The aim of this study was to assess in an in-vitro setting the efficiency of a new inferior vena cava filter to intercept emboli. The new filter,...

  • COMMENTARY: Persistent right ventricular dysfunction increased risk for recurrent venous thromboembolism after acute pulmonary embolism. Douketis, James; Kaatz, Scott // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p46 

    The article presents the authors' views about a study which states that persistent right ventricular dysfunction (RVD) increased risk for recurrent venous thromboembolism (VTE) after acute pulmonary embolism (PE). Although the findings of the study has been associated with increased short-term...

  • Pentasaccharides: a New Class of Anticoagulants in Clinical Practice. Abdel-Razeq, Hikmat // Journal of Coagulation Disorders;2010, Vol. 2 Issue 2, p1 

    Venous thromboembolism (VTE) remains a common but preventable disease. Increasing focus on simplicity and efficacy has led to the introduction of a new group of anticoagulants, the synthetic pentasaccharides, substances that specifically inhibit factor Xa activity, producing an antithrombotic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics